SLC22A12抗体—艾普蒂

The SLC22A12 antibody is a critical tool for studying the function and expression of the SLC22A12-encoded protein, URAT1 (urate transporter 1), a key regulator of uric acid homeostasis. URAT1 is primarily localized to the apical membrane of renal proximal tubule cells and mediates the reabsorption of urate from the glomerular filtrate into the bloodstream. Dysregulation of URAT1 activity is implicated in hyperuricemia, gout, and renal underexcretion disorders, making it a therapeutic target for conditions like gout. Antibodies targeting SLC22A12/URAT1 are widely used in biomedical research to investigate its tissue distribution, expression levels under pathological conditions, and interactions with pharmacological inhibitors (e.g., lesinurad) or genetic variants. These antibodies are typically developed in hosts such as rabbits or mice using immunogenic peptides derived from conserved regions of the human URAT1 protein. Validation methods include Western blotting, immunohistochemistry, and immunofluorescence to confirm specificity in human or model organism tissues. Studies utilizing SLC22A12 antibodies have advanced our understanding of urate handling in the kidneys, the impact of mutations on transporter function, and the molecular mechanisms underlying uricosuric therapies. Additionally, they support diagnostic research exploring URAT1 expression patterns in renal diseases or metabolic syndromes. Proper antibody validation remains essential to avoid cross-reactivity with other SLC22 family transporters.